Notable
ILDR-03 · Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
Primary and study completion pushed from Nov 1, 2028 to Oct 30, 2029
Also in this update: Primary endpoint(s) modified
Chuangzhen ChenPhase 2 NCT07339488 Registry history of NCT07339488 on ClinicalTrials.gov (opens the registry)
Updated